{"id":"NCT01398956","sponsor":"UCB Pharma","briefTitle":"An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures","officialTitle":"An Open-label, Multicenter, Long-term, Follow-up Study in Japan to Evaluate the Safety, Tolerability, and Efficacy of Adjunctive Treatment With Oral L059 (Levetiracetam) in Epilepsy Subjects With Generalized Tonic-clonic (GTC) Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2016-04","completion":"2016-04","firstPosted":"2011-07-21","resultsPosted":"2017-03-09","lastUpdate":"2017-08-15"},"enrollment":44,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Generalized Tonic-clonic Seizures"],"interventions":[{"type":"DRUG","name":"Levetiracetam","otherNames":["Keppra, E Keppra"]}],"arms":[{"label":"Levetiracetam","type":"EXPERIMENTAL"}],"summary":"The investigators will provide Levetiracetam treatment to epilepsy subjects in Japan who are judged to benefit from continued treatment with Levetiracetam by the investigators and who are willing to continuously receive this drug.","primaryOutcome":{"measure":"Incidence of Treatment Emergent Adverse Events During the Entire Study Period","timeFrame":"Through study completion, an average of 3 years","effectByArm":[{"arm":"Levetiracetam (SS)","deltaMin":626,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":32,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":44},"commonTop":["Nasopharyngitis","Convulsion","Dental caries","Somnolence","Influenza"]}}